- Home
- RPRX vs ESS Comparison
RPRX vs ESS Comparison
Compare RPRX & ESS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | ESS |
|---|---|---|
| Founded | 1996 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 16.9B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RPRX | ESS |
|---|---|---|
| Price | $40.54 | $253.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 16 |
| Target Price | $45.75 | ★ $286.23 |
| AVG Volume (30 Days) | ★ 3.4M | 526.7K |
| Earning Date | 02-11-2026 | 02-04-2026 |
| Dividend Yield | 2.33% | ★ 4.05% |
| EPS Growth | N/A | ★ 53.64 |
| EPS | 1.75 | ★ 13.15 |
| Revenue | ★ $2,349,844,000.00 | $1,916,711,000.00 |
| Revenue This Year | $37.66 | $3.97 |
| Revenue Next Year | $2.34 | $3.64 |
| P/E Ratio | $23.06 | ★ $19.32 |
| Revenue Growth | 3.70 | ★ 9.37 |
| 52 Week Low | $29.66 | $243.25 |
| 52 Week High | $41.70 | $316.29 |
Technical Indicators
Market Signals| Indicator | RPRX | ESS |
|---|---|---|
| Relative Strength Index (RSI) | 59.05 | 46.47 |
| Support Level | $38.86 | $251.21 |
| Resistance Level | $40.58 | $259.48 |
| Average True Range (ATR) | 0.76 | 5.45 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 58.63 | 49.28 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 258 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.